Practical Pharmacological Treatment of Heart  Failure

Practical Pharmacological Treatment of Heart Failure

SGLT2 inhibition in heart failure with reduced  or preserved ejection fraction

SGLT2 inhibition in heart failure with reduced or preserved ejection fraction

Medical Therapies for Heart Failure with  Reduced Ejection Fraction

Medical Therapies for Heart Failure with Reduced Ejection Fraction

Algorithm for medication optimization in heart failure with reduced ejection fraction

Algorithm for medication optimization in heart failure with reduced ejection fraction

BNP (B-Type Natriuretic Peptide) Ratio/ Urinary cGMP (Cyclic  Guanosine Monophosphate), Sacubitril/Valsartan, and Outcomes  in Heart Failure With Reduced Ejection Fraction

BNP (B-Type Natriuretic Peptide) Ratio/ Urinary cGMP (Cyclic Guanosine Monophosphate), Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction

Sacubitril Valsartan in Aged Patients and Heart Failure with Reduced Ejection Fraction

Sacubitril Valsartan in Aged Patients and Heart Failure with Reduced Ejection Fraction

Practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction

Practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction

Identification and management of worsening heart failure

Identification and management of worsening heart failure

Role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy

Role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy

Power of ARNI in heart failure

Power of ARNI in heart failure